共查询到17条相似文献，搜索用时 437 毫秒
1.
本试验筛选出了具有良好免疫原性的兔瘟强毒株GMH881和兔巴氏杆菌C51-17株,研制出了兔出血症-巴氏杆菌二联灭活苗。确定出二联苗免疫剂量为1.0mL;二联苗在免疫后5d对兔病毒性出血症强毒的保护率达到100%,二联苗免疫后7d对兔巴氏杆菌的保护率均达到80%以上;二联苗免疫家兔后7d兔病毒性出血症HI抗体可达22.75,15d明显上升,二联苗HI效价30d达到最高峰,可达28.0,二联苗在60～120d均可维持在27.0～25.5水平,到180d时抗体水平略有下降,为25.25,二联苗分别在免疫后4个月、6个月用兔出血症强毒攻击,均产生100%保护,在6个月用2个MLD的兔巴氏杆菌攻击,保护率可达70%以上;二联苗4~8℃条件下保存期暂定为1年,25℃条件下暂定为半年。 相似文献
2.
筛选了具有良好免疫原性的兔瘟强毒株GMH881和兔巴氏杆菌C51-17株,研制出了兔出血症-巴氏杆菌二联铝胶灭活苗,对疫苗进行了免疫剂量、免疫产生期、兔出血症抗体测定、免疫保护期、保存期等试验;确定出二联铝胶苗免疫剂量1.0 mL;二联铝胶苗在免疫后7 d对兔病毒性出血症强毒的保护率达到100%,二联苗免疫后10～14 d对兔巴氏杆菌的保护率均达到75%以上;二联铝胶苗的兔病毒出血症抗体测定结果表明：二联铝胶苗免疫家兔后7 d,HI抗体均可达25.0,15 d明显上升,二联苗HI效价60～90 d达到最高峰,最高可达210,二联苗在120～180 d仍可维持在27.0～29.5水平。二联铝胶苗分别在免疫后4个月、6个月用兔出血症强毒攻击均产生100%保护,在6个月用2个MLD的兔巴氏杆菌攻击保护率可达70%以上,二联铝胶苗4～8℃条件下保护期暂定为1年,25℃条件下暂定为半年。 相似文献
3.
4.
用兔出血症毒(RHDV)和巴氏杆菌研制成蜂胶佐剂灭活苗,用1.0mL免疫试验兔,免疫后第5天,对RHDV保护率达100%;免疫后第7天对巴氏杆菌的保护率为72.5%,通过HI法监测兔病毒性出血症抗体水平,结果表明:蜂胶苗产生抗体时间较早,第7天后HI效价25.0,第20天效价显著上升达29.25以上,第30天达到最高峰,可达211.0,60~120 d均可维持在27.0~25.5水平,到第180天时抗体水平面略有下降为25.25,蜂胶苗分别在免疫后4个月、6个月用兔出血症强毒攻击均产生100%保护,在6个月用2个MLD的兔巴氏杆菌攻击保护率可达70%以上,二联苗4~8℃条件下保存期暂定为1年,25℃条件下暂定为半年。 相似文献
5.
6.
采用对本地区具有良好免疫原性的兔病毒性出血症强毒株和巴氏杆菌菌株,研制出常规二联灭活苗和蜂胶二联灭活苗.用血清学方法对常规二联灭活苗和蜂胶二联灭活苗免疫后兔病毒性出血症抗体的检测.结果表明:常规二联灭活苗免疫后7 d HI抗体可达5.0log2,15 d明显上升,达5.510g2,30 d达到高峰,可达8.0log2,;而蜂胶二联灭活苗在免疫后7 d HI抗体可达5.0log,15d明显上升,达5.5log2以上,20 d显著上升9.25log2以上,30 d达到高峰,可达11.0log2.说明蜂胶提高抗体效价作用明显,可显著增强免疫效果. 相似文献
7.
兔病毒性出血症、多杀性巴氏杆菌病二联蜂胶灭活疫苗分别与两种单苗进行免疫效力、免疫持续期及保存期的试验,试验结果表明:二联蜂胶灭活疫苗对兔病毒性出血症的免疫保护率为100%(10/10),对多杀性巴氏杆菌病的免疫保护率为90%(9/10),而两种单苗的免疫保护均为100%(10/10);二联苗和单苗免疫后第3天对兔病毒性出血症产生部分免疫力,至第10天产生坚强免疫力而对多杀性巴氏杆菌第14天产生坚强免疫力;二联苗和单苗免疫6个月后,对兔病毒性出血症的免疫保护为100%(10/10),对多杀性巴氏杆菌病的免疫保护为90%(9/10);二联苗和单苗在2~8℃和室温条件下保存15个月后,对兔病毒性出血症的免疫保护为100%(10/10),对多杀性巴氏杆菌病的免疫保护为90%(9/10)。二联苗中两组分的配比科学合理且两者之间无干扰作用。 相似文献
8.
9.
兔病毒性出血症、多杀性巴氏杆菌病、产气荚膜梭菌病(A)型三联灭活疫苗研制 总被引：1，自引：0，他引：1
对 5批兔病毒性出血症、多杀性巴氏杆菌病、产气荚膜梭菌病三联灭活疫苗进行了动物试验 ,结果表明该疫苗安全有效。近期效检对兔病毒性出血症的保护率为 1 0 0 % ,对兔多杀性巴氏杆菌病保护率为 92 % ,对产气荚膜梭菌病 (A)型保护率为 88%。在免疫期试验中 ,免疫 6个月后 ,对兔病毒性出血症保护率为 1 0 0 % ,对多杀性巴氏杆菌病的保护率为 79% ,对产气荚膜梭菌病 (A)型的保护率为 88%。在保存期试验中 ,4～ 8℃保存 1年仍有效。 相似文献
10.
11.
对研制的兔出血症、巴氏杆菌二联灭活苗分别与二种单苗进行了免疫力、免疫产生期、免疫持续保护效果、保存期的比较。结果表明：二联灭活苗对兔出血症RHD、巴氏杆菌病（Pm）的保护率分别100％（15／15）,86．7％（13／15）。而二种单苗的免疫效果分别是100％（12／12）和88．8％（8／9）,经统计学检验差异不显著（P〉0．05）。二联苗和单苗对RHD均100％保护,对于Pm二联苗和单苗第7天都能产生保护力,第10天可产生较坚强的免疫效果。疫苗免疫持续6个月后免疫对RHD、Pm的保护率分别为100％（8／8）、83．3％（10／12）,单苗免疫后对RHD、Pm的保护率分别为100％（6／6）,85．7％（12／14）,免疫效果无显著性差异（P〉0．05）。二联苗和二种单苗在4～8℃和室温条件下保存6个月,对兔病毒性出血症的保护率达100％,对巴氏杆菌病也具有良好的免疫效果。二种组分制苗无干扰现象发生。 相似文献
12.
牛溶血性曼氏杆菌及牛荚膜A型多杀性巴氏杆菌是导致牛呼吸道疾病（bovine respiratory disease,BRD）的重要细菌性病原,每年给养牛业带来巨大的经济损失,目前对其疫苗研究仍显不足。本研究选用牛溶血性曼氏杆菌（Mannheimia haemolytica,Mh） Mh422株和牛荚膜A型多杀性巴氏杆菌（Pasteurella multocida,Pm） PmCQ2株作为疫苗菌株,分别制备了2种菌体浓度的Mh和Pm单价灭活菌苗及3种菌量配比（1∶1、2∶1和3∶1）的Mh-Pm二联灭活苗,以小鼠为模型,皮下多点免疫（0.2 mL）,加强免疫2次,免疫剂量均为首免的一半。首免后第7天及其后每隔5 d,小鼠尾静脉采血分离血清,ELISA方法检测抗体效价,三免后第20天,分别以Mh422或PmCQ2进行腹腔攻毒测定免疫保护效果。结果显示,所有小鼠接种疫苗均无不良反应,二免后第10天抗体达较高水平,三免后抗体水平持续升高,第15天到达高峰,其后25 d维持高水平,后缓慢下降。Mh单菌苗的2种免疫剂量对Mh422株攻毒的免疫保护率均为0,而Pm单菌苗的2种免疫剂量对PmCQ2株攻毒的免疫保护率全为100%;Mh和Pm间无交叉免疫保护作用;3种菌量配比的Mh-Pm二联疫苗对Mh422株和PmCQ2株攻毒的各自免疫保护率分别为53%～71%和100%。该研究结果表明,所制备的Mh422单菌苗对同型攻毒无免疫保护作用,在诱导机体抗体产生方面,Mh和Pm间无相互抑制作用,PmCQ2株具有促进Mh422株灭活疫苗对Mh422的免疫保护作用,这为牛溶血性曼氏杆菌和牛多杀性巴氏杆菌二联疫苗的进一步研究提供了理论基础。 相似文献
13.
14.
15.
将鸡新城疫、禽流感（H9亚型,SY株）二联灭活疫苗与市售同类对照苗分不同剂量皮下注射接种30日龄SPF鸡,免疫后定期采血,分离血清,通过检测血清中ND和AI的HI抗体水平比较各组鸡抗体产生期、抗体高峰及免疫持续期,并进行不同血凝抗原检测HI抗体结果的对比。试验鸡血清样品检测结果显示,免疫鸡抗体产生期为免后2周内,免后8周和5周ND和AI的HI抗体滴度分别达到峰值,抗体至少可持续28周以上,两种灭活苗之间免疫效果基本相当。 相似文献
16.
Knowledge of the dose-response relation of inactivated vaccines and of the factors that influence this relation is essential for the evaluation of existing vaccine potency assays and the development of new potency assays that are based on the antigen content of the inactivated vaccines. We quantified the relation between vaccine dose, serologic response, and clinical protection after vaccination for three different inactivated Newcastle disease (ND) vaccines. Qualitatively, similar dose-response curves were obtained for the three vaccines when either the serologic response or the clinical protection of specific-pathogen-free (SPF) chickens was plotted against the different vaccine doses applied. However, the vaccines differed quantitatively: doses of vaccines that induced similar antibody titers or clinical protection differed 2-8-fold. In contrast with the narrow range of antibody titers induced by a full vaccine dose, a very broad range of titers was obtained after dilution of the vaccines. At least 95% of the SPF chickens with detectable antibody in the serum were protected against a challenge with virulent Herts ND virus. The relation between the dosage of two different ND vaccines and the serum antibody titers remained markedly constant between 3 and 18 wk after vaccination. Vaccination of broilers instead of layers with a dilution series of inactivated ND vaccine resulted in significantly lower antibody levels and less clinical protection against virulent challenge. In conclusion, despite quantitative differences, we found comparable dose-response relations for the three inactivated ND vaccines studied. 相似文献
17.
SUN Pu HE Wei FU Yuanfang LI Dong YANG Lin WEI Delong CAO Yimei LI Pinghua BAI Xingwen MA Xueqing LI Kun BAO Huifang ZHANG Jing ZHU Xinrong LIU Zaixin LU Zengjun 《畜牧兽医学报》1956,51(10):2481-2489
Vaccination with inactivated vaccine is an important measure to prevent and control foot-and-mouth disease (FMD), however, the immune effect and antigenic purity of inactivated vaccines are two major concerns for the establishment and evaluation of FMD free zones with vaccination. In this study, four groups of FMD type O and type A bivalent inactivated vaccines from 3 FMD vaccine manufacturers (designated as A, B and C) were selected to inoculate healthy juvenile cattle of FMD free. All cattle were immunized 3 or 4 times at a 1-month interval. Serum samples were collected before and after 1 month of every vaccination to determine the level of antibody to structural protein and non-structural protein. Results：(1) The qualified rates of antibody to structural protein: in group a1 (vaccine from company A, different batches), the antibody qualified rate could reach 100% for type O and type A, respectively after each vaccination. In group a2 (vaccines from company A, same batch), the antibody qualified rates were 36.7%, 98.3% and 100% for type O, and 15%, 86.7% and 100% for type A after the first to the third vaccination, respectively. In group b (vaccine from company B, same batch), the antibody qualified rates were 18.3%, 97% and 100% for type O, and 1.7%, 45% and 53.3% for type A after the first to the third vaccination, respectively. In group c (vaccines from company C, same batch), the antibody qualified rates were 26.7%, 96.7% and 100% for type O, and 21.7%, 71.7% and 100% for type A after the first to the third vaccination, respectively. (2) Antibody positive rate to non-structural protein 3ABC (confirmed with second ELISA test): In group a1, the positive rates were 0.7%, 1.4%, 9.5% and 4.8% after the first to the fourth vaccination, respectively; In group a2 and c, no 3ABC antibody-positive animal was detected after 3 repeated vaccination; In Group b, only one animal with a positive rate of 0.6% was detected after the third vaccination. The antibody qualified rates to the structural protein of FMDV in 3 of the 4 groups were far less than 70% after the primary vaccination, however, those were increased significantly after boost and repeated vaccination. The antigen purity of vaccines in three groups (a2, b and c) can meet the requirement of OIE standard on the FMD vaccine, however, the seroconversion to 3ABC antibody was obvious in animals from group a1 after repeated vaccination, which would cause some extent of interference to differential diagnosis. Also, a combination of a primary screening test and a confirmatory ELISA test can further improve the accuracy of differential diagnosis. This study provides an important scientific basis to make a rational program for establishment and evaluation of FMD free zone with vaccination. 相似文献